Welcome to our dedicated page for Pulse Biosciences news (Ticker: PLSE), a resource for investors and traders seeking the latest updates and insights on Pulse Biosciences stock.
Pulse Biosciences Inc (NASDAQ: PLSE) pioneers bioelectric medicine through its proprietary Nano-Pulse Stimulation technology, offering investors and medical professionals a novel approach to non-thermal therapies. This dedicated news hub provides real-time updates on clinical advancements, regulatory developments, and strategic partnerships shaping the future of targeted cellular treatments.
Access verified information about PLSE's progress in immuno-oncology applications, dermatology research breakthroughs, and system commercialization efforts. Our curated feed includes earnings reports, FDA submissions, peer-reviewed study results, and executive commentary – all essential for evaluating the company's position in the electroceuticals market.
Key updates cover therapeutic trial milestones, intellectual property expansions, and collaborations with leading medical institutions. Bookmark this page to monitor how PLSE's drug-free energy modalities could transform treatment protocols for complex conditions while driving long-term value in the medical device sector.
Pulse Biosciences, Inc. (Nasdaq: PLSE) reported no revenue in Q4 2022 due to the discontinuation of commercial dermatology activities. For the full year, revenue reached $700,000, primarily from earlier in the year. Q4 GAAP expenses decreased to $8.7 million from $16.3 million YoY, while the net loss shrank to $9.2 million from $15.4 million. Total cash reserves increased to $61.1 million as of December 31, 2022, up from $28.6 million in 2021. The company is focused on developing NS PFA delivery devices for atrial fibrillation treatments, with a pre-submission meeting with the FDA planned for 2Q23.
Pulse Biosciences, Inc. (PLSE) announced it will release its financial results for Q4 and the full year of 2022 on March 30, 2023, after market close. A conference call will follow at 1:30 PM PT / 4:30 PM ET. The company is focused on its proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for treating atrial fibrillation, aiming to enhance patient outcomes. Investors can join the call by dialing 1-877-704-4453 domestically or 1-201-389-0920 internationally. More details are available on their website.
Pulse Biosciences (NASDAQ: PLSE) announced its nsPFA™ System showcased in a poster presentation at the 28th Annual International AF Symposium in Boston from February 2-4. The technology integrates with CardioNXT’s iMap system, demonstrating effective cardiac ablation and mapping capabilities. The preclinical studies suggest that the nsPFA System may improve patient outcomes by combining advanced technologies for treating atrial fibrillation. CEO Kevin Danahy indicated optimism about early results, emphasizing the potential of the new catheter system.
Pulse Biosciences (PLSE) released its third-quarter financial results for 2022, reporting no revenue and a GAAP net loss of $18.0 million, up from a loss of $14.3 million in Q3 2021. Total expenses rose to $18.0 million, including a $7.2 million inventory reserve for dermatology. Cash reserves improved to $69.2 million, compared to $14.8 million in Q2 2022. The company is focusing on cardiac ablation for atrial fibrillation and anticipates a quarterly cash burn of approximately $8 million starting Q1 2023. A $65 million term loan was secured from the Executive Chairman to support product development.
FAQ
What is the current stock price of Pulse Biosciences (PLSE)?
What is the market cap of Pulse Biosciences (PLSE)?
